Posted by morton13 on 10th of Jun 2014 at 09:27 am
reason for their decline yesterday...
And, by the way, there was more on the M&A front. Merck (MRK)
announced it would buy
IdentixPharmaceuticals (IDIX) for a mind-blowing
premium of 229%, at $24.50, or 3x the Friday price. IDIX has an
experimental Hepatitis C drug, which is why the top Hep C therapy
maker, Gilead Sciences (GILD), turned pale today, falling
4%.
Newsletter
Subscribe to our email list for regular free market updates
as well as a chance to get coupons!
GILD
Posted by morton13 on 10th of Jun 2014 at 09:27 am
reason for their decline yesterday...
And, by the way, there was more on the M&A front. Merck (MRK) announced it would buy IdentixPharmaceuticals (IDIX) for a mind-blowing premium of 229%, at $24.50, or 3x the Friday price. IDIX has an experimental Hepatitis C drug, which is why the top Hep C therapy maker, Gilead Sciences (GILD), turned pale today, falling 4%.